Monica Miozzo

Prof. Monica Miozzo

Department of Health Science, University of Milan, Milan, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2004 in The Lancet
Verified
Journal Article
Closed access
PIPietro Invernizzi
Pietro Invernizzi
MMMonica Miozzo
Monica Miozzo
PBPier Maria Battezzati
Pier Maria Battezzati
IBIlaria Bianchi
Ilaria Bianchi
FGFrancesca R Grati
Francesca R Grati
MPMauro Podda
Mauro Podda

1 March 1992 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MPM A Pierotti
M A Pierotti
MSM Santoro
M Santoro
RJR B Jenkins
R B Jenkins
GSgabriella sozzi
gabriella sozzi
IBItalia Bongarzone
Italia Bongarzone
Alfredo FuscoAlfredo Fusco
Alfredo Fusco
RET/PTC is a transforming sequence created by the fusion of the tyrosine kinase domain of the RET protooncogene with the 5' end of the locus D10S170 designated by probe H4 and is frequently found activated in human papillary thyroid carcinomas. RET and D10S170 have been mapped to contiguous regions of the long arm of chromosome 10: q11.2 and q21, respectively. To identify the mechanism leading to the generation of the oncogenic sequence RET/PTC, a combined cytogenetic and molecular analysis of several cases of papillary thyroid carcinomas was done. In four cases the results indicated that these tumors had RET/PTC activation and a paracentric inversion of the long arm of chromosome 10, inv(10)(q11.2q21), with breakpoints coincident with the regions where RET and D10S170 are located. Therefore, a chromosome 10q inversion provides the structural basis for the D10S170-RET fusion that forms the hybrid transforming sequence RET/PTC.

1 July 2005 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
PIPietro Invernizzi
Pietro Invernizzi
MMMonica Miozzo
Monica Miozzo
CSCarlo Selmi
Carlo Selmi
LPLuca Persani
Luca Persani
PBPier Maria Battezzati
Pier Maria Battezzati
MPMauro Podda
Mauro Podda
The majority of human autoimmune diseases are characterized by female predominance. Although sex hormone influences have been suggested to explain this phenomenon, the mechanism remains unclear. In contrast to the role of hormones, it has been suggested, based on pilot data in primary biliary cirrhosis, that there is an elevation of monosomy X in autoimmune disease. Using peripheral white blood cells from women with systemic sclerosis (SSc), autoimmune thyroid disease (AITD), or healthy age-matched control women, we studied the presence of monosomy X rates using fluorescence in situ hybridization. We also performed dual-color fluorescence in situ hybridization analysis with a chromosome Y α-satellite probe to determine the presence of the Y chromosome in the monosomic cells. In subsets of patients and controls, we determined X monosomy rates in white blood cell subpopulations. The rates of monosomy X increased with age in all three populations. However, the rate of monosomy X was significantly higher in patients with SSc and AITD when compared with healthy women (6.2 ± 0.3% and 4.3 ± 0.3%, respectively, vs 2.9 ± 0.2% in healthy women, p < 0.0001 in both comparisons). Importantly, X monosomy rate was more frequent in peripheral T and B lymphocytes than in the other blood cell populations, and there was no evidence for the presence of male fetal microchimerism. These data highlight the thesis that chromosome instability is common to women with SSc and AITD and that haploinsufficiency for X-linked genes may be a critical factor for the female predominance of autoimmune diseases.

16 November 2016 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
LFL. Fontana
L. Fontana
BGB. Gentilin
B. Gentilin
LFL. Fedele
L. Fedele
CGCristina Gervasini
Cristina Gervasini
MMMonica Miozzo
Monica Miozzo

19 April 2017 in Italian Journal of Pediatrics
Verified
Journal Article
Open access
PDF file
CCClaudia Ciaccio
Claudia Ciaccio
LFLaura Fontana
Laura Fontana
DMDonatella Milani
Donatella Milani
STSilvia Maria Tabano
Silvia Maria Tabano
MMMonica Miozzo
Monica Miozzo
Susanna EspositoSusanna Esposito
Susanna Esposito
Fragile X Syndrome (FXS) is the second cause of intellectual disability after Down syndrome and the most prevalent cause of intellectual disability in males, affecting 1:5000–7000 men and 1:4000–6000 women. It is caused by an alteration of the FMR1 gene, which maps at the Xq27.3 band: more than 99% of individuals have a CGG expansion (>200 triplets) in the 5′ UTR of the gene, and FMR1 mutations and duplication/deletion are responsible for the remaining (<1%) molecular diagnoses of FXS. The aim of this review was to gather the current clinical and molecular knowledge about FXS to provide clinicians with a tool to guide the initial assessment and follow-up of FXS and to offer to laboratory workers and researchers an update about the current diagnostic procedures. FXS is a well-known condition; however, most of the studies thus far have focused on neuropsychiatric features. Unfortunately, some of the available studies have limitations, such as the paucity of patients enrolled or bias due to the collection of the data in a single-country population, which may be not representative of the average global FXS population. In recent years, insight into the adult presentation of the disease has progressively increased. Pharmacological treatment of FXS is essentially symptom based, but the growing understanding of the molecular and biological mechanisms of the disease are paving the way to targeted therapy, which may reverse the effects of FMRP deficiency and be a real cure for the disease itself, not just its symptoms. The clinical spectrum of FXS is wide, presenting not only as an isolated intellectual disability but as a multi-systemic condition, involving predominantly the central nervous system but potentially affecting any apparatus. Given the relative high frequency of the condition and its complex clinical management, FXS appears to have an important economic and social burden.

4 November 2009 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
LBLaura Bernardini
Laura Bernardini
SGStefania Gimelli
Stefania Gimelli
CGCristina Gervasini
Cristina Gervasini
MCMassimo Carella
Massimo Carella
ABAnwar Baban
Anwar Baban
BDBruno Dallapiccola
Bruno Dallapiccola
Background: Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH) consists of congenital aplasia of the uterus and the upper part of vagina due to anomalous development of Müllerian ducts, either isolated or associated with other congenital malformations, including renal, skeletal, hearing and heart defects. This disorder has an incidence of approximately 1 in 4500 newborn girls and the aetiology is poorly understood. Methods and Results: we report on two patients affected by MRKH syndrome in which array-CGH analysis disclosed an identical deletion spanning 1.5 Mb of genomic DNA at chromosome 17q12. One patient was affected by complete absence of uterus and vagina, with bilaterally normal ovaries, while the other displayed agenesis of the upper part of vagina, right unicornuate uterus, non cavitating rudimentary left horn and bilaterally multicystic kidneys. The deletion encompassed two candidate genes, TCF2 and LHX1. Mutational screening of these genes in a selected group of 20 MRKH females without 17q12 deletion was negative. Conclusion: Deletion 17q12 is a rare albeit recurrent anomaly mediated by segmental duplications, previously reported in subjects with developmental kidney abnormalities and diabetes. The present two patients expand the clinical spectrum associated with this imbalance and suggest that this region is a candidate locus for a subset of MRKH syndrome individuals, with or without renal defects.